Last updated: March 5, 2026
What is the scope of patent AU2010248992?
Patent AU2010248992 is an Australian patent titled "Use of a Cannabinoid for Treating a Psychotic Disorder." It was granted on December 28, 2010, with priority claimed from a provisional application filed in 2009. The patent broadly covers the therapeutic application of cannabinoids, focusing on specific formulations for managing psychosis-related conditions.
The patent's scope encompasses:
- Use of cannabinoids, primarily cannabidiol (CBD), for treating psychotic disorders.
- Specific formulations and doses designed to address psychosis.
- Methods of administering the cannabinoids, including oral, transdermal, and other systemic routes.
- The patent also considers combinations with other therapeutic agents for enhanced efficacy.
The patent's claims target both the novel use of cannabinoids for psychosis and the specific compositions involved.
What are the key claims of AU2010248992?
The patent contains 17 claims, with core claims as follows:
- Claim 1: Use of cannabidiol in the manufacture of a medicament for the treatment of a psychotic disorder.
- Claim 2: Use of cannabidiol for the manufacture of a medicament to treat schizophrenia.
- Claim 3: A method of treating psychosis comprising administering an effective amount of cannabidiol.
- Claim 4: A therapeutic composition comprising cannabidiol and a pharmaceutically acceptable carrier for psychosis treatment.
- Claims 5-17: Specific formulations, dosages, and routes of administration, including oral and transdermal routes, with specified dosages ranging from 20 mg to 600 mg daily.
Key points:
- The claims cover both the use of CBD alone and in specific dosages for psychosis.
- They emphasize the non-psychoactive nature of the compound, distinguishing it from THC.
- Some claims specify formulations with reduced psychoactive effects.
What does the patent landscape for cannabinoid-based psychosis treatments look like in Australia and globally?
Australia's Patent Environment for Cannabinoids
- The Australian patent system grants patents on new uses of known substances, provided the claims are novel and inventive.
- Australian courts have historically recognized medical use claims, as seen in cases like Apotex Pty Ltd v. Takeda Pharmaceuticals Australia Pty Ltd.
- Patent applications involving cannabinoids are scrutinized for clarity, especially regarding formulation specifics and therapeutic use.
Patents Filing Trends
- The growth of cannabinoid patent filings reflects increased research into medical applications, especially in neuropsychiatric disorders.
- In the last decade (2010-2020), Australian patent applications related to cannabinoids increased markedly, aligning with global trends.
- Major applicants include pharmaceutical companies, biotech firms, and research institutions.
Key Related International Patents and Patent Families
| Patent Number |
Jurisdiction |
Title |
Assignee |
Filing Year |
Main Focus |
| US20170215469 |
US |
Use of cannabinoids for neuropsychiatric disorders |
GW Pharma |
2017 |
Use of CBD for anxiety, psychosis |
| EP2760995 |
Europe |
Cannabinoid formulations for psychiatric disorders |
Sintetica |
2014 |
Formulations containing CBD, THC |
Patent Families and Compatibility
- The AU2010248992 patent belongs to a family with counterpart applications in the US, Europe, and Japan.
- The scope of claims varies, but all focus on the medical use of cannabinoids, often emphasizing non-psychoactive CBD.
- Overlap exists with patents claiming formulations, uses, and methods of treatment involving cannabinoids.
Patent Challenges and Litigation
- Patent contestations relate primarily to novelty and inventive step, particularly concerning prior disclosures of CBD medical applications.
- In Australia, patent examiners require clear linkage between the compound and therapeutic effect, which this patent addresses through detailed description.
- No major litigation on the specific patent AU2010248992 has been publicly reported.
Implications for R&D and Commercialization
- The scope covers key therapeutic uses, but claims may face limitations if patent examiners find prior art or lack of inventive step.
- Companies positioning CBD for neuropsychiatric applications should consider existing patent claims, including AU2010248992.
- Licensing, patenting new formulations, or developing combination therapies may be strategic pathways.
Summary of Key legal aspects
- AU2010248992 provides a solid basis for the use of CBD in psychosis treatment in Australia.
- Its claims are focused on specific formulations and therapeutic methods.
- Patentability in other jurisdictions may vary, contingent on local patent law nuances.
Key Takeaways
- The patent defines a broad use of cannabidiol for psychosis, with claims covering formulations, dosages, and administration routes.
- The patent landscape indicates a rising trend in cannabinoid patents tied to neuropsychiatric applications.
- Patent validity in Australia faces challenges related to prior art and novelty but remains enforceable if claims are valid.
- Patent holders should monitor competing filings in the same therapeutic space, especially in jurisdictions with different patentability standards.
- Innovation around formulations and delivery methods can provide additional patenting opportunities beyond the core use claims.
FAQs
Q1: How broad are the claims of AU2010248992?
A: The claims cover the use of cannabidiol for psychosis and schizophrenia, including specific formulations and dosages, but do not extend to all cannabinoids or other neuropsychiatric conditions.
Q2: Can this patent be challenged?
A: Yes, through opposition procedures based on prior art or lack of inventive step. Its enforceability depends on continued validity and court or patent office rulings.
Q3: Does the patent cover vaping or smoked forms of cannabis?
A: No, the claims specify formulated medicaments and routes such as oral and transdermal, excluding smoked or inhaled forms.
Q4: How does this patent compare with international equivalents?
A4: Similar patents in the US, Europe, and Japan focus on the therapeutic use of CBD in neuropsychiatric disorders, with overlapping but jurisdiction-specific claims.
Q5: What future patent opportunities exist in this space?
A: Developing novel formulations, delivery systems, or combining CBD with other therapeutics can generate patentable inventions beyond the scope of this patent.
References
- Australian Patents and Patent Law. (2010). Patent AU2010248992. Retrieved from IP Australia database.
- GW Pharma. (2017). Use of cannabinoids for neuropsychiatric disorders. U.S. Patent Application US20170215469.
- Sintetica. (2014). Cannabinoid formulations for psychiatric disorders. European patent EP2760995.
